1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Hypercholesterolemia Partnering 2010-2015

Global Hypercholesterolemia Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Hypercholesterolemia Partnering 2010-2015 report provides understanding and access to the hypercholesterolemia partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in hypercholesterolemia partnering deals
Top hypercholesterolemia deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Hypercholesterolemia Partnering 2010-2015 provides understanding and access to the hypercholesterolemia partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of hypercholesterolemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors hypercholesterolemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual hypercholesterolemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of hypercholesterolemia partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of hypercholesterolemia technologies and products.

Report scope

Hypercholesterolemia Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to hypercholesterolemia trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in hypercholesterolemia dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 50 hypercholesterolemia deals and contract documents where available
The leading hypercholesterolemia deals by value since 2010

In Hypercholesterolemia Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Hypercholesterolemia Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of hypercholesterolemia deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 50 actual hypercholesterolemia deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Hypercholesterolemia Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hypercholesterolemia partnering

2.1. Introduction
2.2. Hypercholesterolemia partnering over the years
2.3. Hypercholesterolemia partnering by deal type
2.4. Hypercholesterolemia partnering industry sector
2.5. Hypercholesterolemia partnering by stage of development
2.6. Hypercholesterolemia partnering by technology type

Chapter 3 - Average deal terms for hypercholesterolemia

3.1 Introduction
3.2 Average deal terms for hypercholesterolemia
3.3 Hypercholesterolemia headline values with median calculation
3.4 Hypercholesterolemia upfront values with median calculation
3.5 Hypercholesterolemia milestone values with median calculation
3.6 Hypercholesterolemia royalty rates with median calculation

Chapter 4 - Active hypercholesterolemia dealmakers

4.1. Introduction
4.2 Most active hypercholesterolemia dealmakers
4.3. Top hypercholesterolemia deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Hypercholesterolemia dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Hypercholesterolemia partnering since 2010
Figure 2: Hypercholesterolemia dealmaking activity- 2010 to 2015
Figure 3: Hypercholesterolemia partnering by deal type since 2010
Figure 4: Hypercholesterolemia partnering by industry sector since 2010
Figure 5: Hypercholesterolemia partnering by stage of development since 2010
Figure 6: Hypercholesterolemia partnering by technology type since 2010
Figure 7: Hypercholesterolemia deals with a headline value
Figure 8: Hypercholesterolemia deals with upfront payment values
Figure 9: Hypercholesterolemia deals with milestone payments
Figure 10: Hypercholesterolemia deals with royalty rates, %
Figure 11: Top hypercholesterolemia deals by value since 2010
Figure 12: Big pharma - top 50 - hypercholesterolemia deals 2010 to 2015
Figure 13: Big pharma hypercholesterolemia deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - hypercholesterolemia deals 2010 to 2015
Figure 15: Big biotech hypercholesterolemia deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.